Mergers & AcquisitionsBy The Online Investor Staff, updated Wed., Feb. 26, 1:49 PM
|This Slide: #81 of 100|
Slide #81. AXIM Biotechnologies, Inc. — Sapphire Biotech, Inc.
AXIM Biotechnologies, Inc. (AXIM)
Sapphire Biotech, Inc.
AXIM Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM Biotech," "AXIM" or "the Company"), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its acquiree Sapphire Biotech, Inc. ("Sapphire") has signed a Sponsored Research Agreement ("SRA") with Arizona State University ("ASU") to conduct preclinical studies using Quiescin Sulfhydryl Oxidase 1 ("QSOX1") inhibitors as anti-neoplastic compounds.